Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2528922 | 0.81 | NPC1 (0.38) | NPC1RAB9A | |
| SCHEMBL7857559 | 0.78 | — | — | |
| SCHEMBL7857319 | 0.76 | — | — | |
| SCHEMBL2529645 | 0.74 | KDM4E (0.34) | NPC1RAB9A | |
| SCHEMBL25590443 | 0.74 | NPC1 (0.36) | NPC1RAB9A | |
| SCHEMBL25591826 | 0.69 | ABL1 (0.40) | NPC1RAB9A | |
| SCHEMBL25593744 | 0.69 | RAB9A (0.41) | NPC1RAB9A | |
| SCHEMBL19622195 | 0.68 | MAPT (0.44) | NPC1RAB9A | |
| SCHEMBL2533266 | 0.67 | KDM4E (0.39) | NPC1RAB9A | |
| SCHEMBL29404769 | 0.67 | NPC1 (0.52) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160318955-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9416146-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150291629-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, LLC | 2015-10-15 | — | — | US | disclosed |
| US-9012431-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140011768-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, LLC | 2014-01-09 | — | — | US | disclosed |
| US-8461135-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120214765-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8039450-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011768-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, CD68 | NPC1 1757/4885RAB9A 1885/4885 |
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | NFKBIA, LITAF, CD68 | NPC1 1757/4885RAB9A 1885/4885 |
| US-20160318955-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | NFKBIA, LITAF, CD68 | NPC1 1757/4885RAB9A 1885/4885 |
| US-20150291629-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | NFKBIA, LITAF, CD68 | NPC1 1757/4885RAB9A 1885/4885 |
| US-20120214765-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, CD68 | NPC1 1757/4885RAB9A 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.